Boston, MA -- (SBWIRE) -- 12/12/2016 -- Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes almost 85%-90% of the total diagnosed cases. It grows and spreads quite slowly.

Technavio's analysts forecast the global lung cancer therapeutics market to contribute around $11.19 billion during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global lung cancer therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent lung cancer therapeutics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

Get More Details on this Report and a Full Table of Contents at Global Lung Cancer Therapeutics Market 2016-2020

The market is divided into the following segments based on geography:

-Americas
-APAC
-EMEA

Technavio's report, Global Lung Cancer Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

-F. Hofmann-La Roche
-Eli Lilly
-AstraZeneca
-Pfizer
-Celgene

Other prominent vendors

-Abbvie
-Aetna
-Agennix
-Allergan
-Amgen
-ARIAD Pharmaceuticals
-Astellas Pharma
-Betta Pharmaceuticals
-BeyondSpring Pharmaceuticals
-BioNumerik Pharmaceuticals
-Boehringer Ingelheim
-Boston Biomedical
-Bristol-Myers Squibb
-Celldex
-CTI BioPharma
-Eisai
-GlaxoSmithKline
-GTx
-Helsinn
-Hutchison Medipharma
-Ionis Pharmaceuticals
-Kadmon Corporation
-MabVax
-Merck
-Novartis
-NovaRx Corporation
-OncoGeneX
-Ono Pharmaceutical
-OSE Immunotherapeutics
-OSI Pharmaceuticals
-Peregrine
-PharmaMar
-Pierre Fabre
-Qiagen
-Recombio
-Samsung Bioepis
-Sanofi
-SFJ Pharmaceuticals
-Spectrum Pharmaceuticals
-Sumitomo Dainippon Pharma
-Synta
-Takeda Pharmaceuticals
-Teva Pharmaceutical
-Xcovery

Market driver

-Growing demand for targeted therapies
-For a full, detailed list, view our report

Market challenge

-Growing popularity of alternative therapeutics
-For a full, detailed list, view our report

Market trend

-Emergence of nanomedicine platform for the treatment of lung cancer
-For a full, detailed list, view our report

Key questions answered in this report

-What will the market size be in 2020 and what will the growth rate be?
-What are the key market trends?
-What is driving this market?
-What are the challenges to market growth?
-Who are the key vendors in this market space?
-What are the market opportunities and threats faced by the key vendors?
-What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: F. Hofmann-La Roche, Eli Lilly, AstraZeneca, Pfizer, Celgene, Abbvie, Aetna, Agennix, Allergan, Amgen, ARIAD Pharmaceuticals, Astellas Pharma, Betta Pharmaceuticals, BeyondSpring Pharmaceuticals, BioNumerik Pharmaceuticals, Boehringer Ingelheim, Boston Biomedical, Bristol-Myers Squibb, Celldex, CTI BioPharma, Eisai, GlaxoSmithKline, GTx, Helsinn, Hutchison Medipharma, Ionis Pharmaceuticals, Kadmon Corporation, MabVax, Merck, Novartis, NovaRx Corporation, OncoGeneX, Ono Pharmaceutical, OSE Immunotherapeutics, OSI Pharmaceuticals, Peregrine, PharmaMar, Pierre Fabre, Qiagen, Recombio, Samsung Bioepis, Sanofi, SFJ Pharmaceuticals, Spectrum Pharmaceuticals, Sumitomo Dainippon Pharma, Synta, Takeda Pharmaceuticals, Teva Pharmaceutical, Xcovery

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:
-Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2016
-Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics
-Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market
-Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence
-Head And Neck Cancer Global Clinical Trials Review, H1, 2016